Our experts will be onsite at JP Morgan (San Francisco, January 8-11). Join them to explore commercialization models and options for your assets. EVERSANA offers alternatives to selling, out-licensing or launching internally. Join us for a conversation.
Schedule a meeting for:
Since its launch in 2018, EVERSANA has built the industry’s first fully integrated commercialization solution, serving more than 650 partners ranging from established pharmaceutical companies to emerging start-ups.
EVERSANA’s global commercial services are recognized for improving the launch and long-term in-market success for products across more than 50 therapeutic indications, including oncology, as well as advanced digital therapeutics.
Explore a few of our commercial models:
- EVERSANA COMPLETE COMMERCIALIZATION – full access to ready-to-deploy, high-performance commercialization and distribution engine; mitigate the risk of having to build commercial infrastructure
- EVERSANA REIGNITE – built for large pharma established brand portfolios – Maximize product value before its loss of exclusivity, and optimize revenue at the late stages of the product life cycle